<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMMONIUM CHLORIDE</span><br/>(ah-mo'ni-um)<br/><b>Classifications:</b> <span class="classification">electrolytic balance and water balance agents</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>26.75% or 5 mEq/mL solution; 500 mg tablets; 486 mg enteric-coated tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Acidifying property is due to conversion of ammonium ion (NH<sub>4</sub><sup>+</sup>) to urea in liver with liberation of H<sup>+</sup> and Cl<sup></sup>. Potassium excretion also increases acid, but to a lesser extent. Tolerance to diuretic effect occurs within 23 d.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Systemic acidifier in metabolic alkalosis by releasing H<sup>+</sup> ions which lower pH.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hypochloremic states and metabolic alkalosis. Diuretic or urinary acidifying agent.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe renal or hepatic insufficiency; primary respiratory acidosis. Safety during pregnancy (category B) or lactation is
         not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiac edema, pulmonary insufficiency.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urine Acidifier, Diuretic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 412 g/d divided q46h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 75 mg/kg/d in 4 divided doses<br/><br/><span class="indicationtitle">Metabolic Alkalosis and Hypochloremic States</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> Dose calculated on basis of CO<sub>2</sub> combining power or serum Cl deficit, 50% of calculated deficit is administered slowly<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give after meals for best tolerance or use enteric-coated tablets. Tablets should be swallowed whole.</li>
<li>Store in airtight container.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Check with physician for slower rate for infants.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Dilute each 20 ml vial in 500 mL NS. Do not exceed a concentration of 12%.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span>  Give slowly to avoid serious adverse effects (ammonia toxicity) and local irritation and pain. Give at a rate not to exceed
                  5 mL/min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Codeine phosphate,</b>
<b>levorphanol,</b>
<b>methadone,</b>
<b>nitrofurantoin,</b>
<b>warfarin</b>. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Avoid freezing.</li>
<li>Concentrated solutions crystallize at low temperatures. </li>
<li>Crystals can be dissolved by placing intact container in a warm water bath and warming to room temperature.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Most secondary to ammonia toxicity. <span class="typehead">CNS:</span> Headache, depression, drowsiness, twitching, excitability; EEG abnormalities. <span class="typehead">CV:</span> Bradycardia and other arrhythmias. <span class="typehead">GI:</span> Gastric irritation, nausea, vomiting, anorexia. <span class="typehead">Metabolic:</span> Metabolic acidosis, hyperammonia. <span class="typehead">Skin:</span> Rash. <span class="typehead">Respiratory:</span> Hyperventilation. <span class="typehead">Skin:</span> Rash. <span class="typehead">Urogenital:</span> Glycosuria <span class="typehead">Other:</span> Pain and irritation at IV site. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Ammonium chloride may increase <span class="alt">blood ammonia</span> and <span class="alt">AST,</span> decrease <span class="alt">serum magnesium</span> (by increasing urinary magnesium excretion), and decrease <span class="alt">urine urobilinogen.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aminosalicylic acid</b> may cause crystalluria; increases urinary excretion of <span class="classification">amphetamines</span>, <b>flecainide,</b>
<b>mexiletine,</b>
<b>methadone,</b>
<b>ephedrine,</b>
<b>pseudoephedrine;</b> decreased urinary excretion of <span class="classification">sulfonylureas</span>, <span class="classification">salicylates</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Completely absorbed in 36 h. <span class="typehead">Metabolism:</span> Metabolized in liver to HCl and urea. <span class="typehead">Elimination:</span> Primarily excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess IV infusion site frequently for signs of irritation. Change site as warranted.</li>
<li>Monitor for S&amp;S of: metabolic acidosis (mental status changes including confusion, disorientation, coma, respiratory changes
            including increased respiratory rate and depth, exertional dyspnea); ammonium toxicity (cardiac arrhythmias including bradycardia,
            irregular respirations, twitching, seizures).
         </li>
<li>Monitor I&amp;O ratio and pattern. The diuretic effect of ammonium chloride is compensatory and lasts only 12 d.</li>
<li>Lab tests: Baseline and periodic determinations of CO<sub>2</sub> combining power, serum electrolytes, and urinary and arterial pH during therapy to avoid serious acidosis.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report pain at IV injection site.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>